ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,202.00
-0.47%
Dow Jones
40,358.09
-0.14%
Brent Oil
80.775
-0.91%
Bitcoin
66,043.80
-2.31%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amylyx Pharmaceuticals Inc (AMLX)

  7. Amylyx Pharmaceuticals Inc (AMLX) News

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateTimeSourceHeadlineSymbolCompany
07/18/20247:00PMPR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/10/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/10/20247:00AMBusiness WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/09/20244:01PMBusiness WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/07/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/07/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/07/20244:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/06/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/04/20249:00AMBusiness WireAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/16/20247:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/09/20247:12AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/09/20247:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/09/20247:00AMBusiness WireAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/08/20249:00AMBusiness WireAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/02/20249:00AMBusiness WireAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/10/20249:00AMBusiness WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/09/20245:45AMPR Newswire (US)The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/08/20249:00AMBusiness WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/05/20245:45AMPR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/04/20247:00AMBusiness WireAmylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and StrategyNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/02/20245:45AMPR Newswire (US)The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/29/20245:45AMPR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/26/20245:45AMPR Newswire (US)Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/25/20248:00AMPR Newswire (US)INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINENASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/22/20245:45AMPR Newswire (US)The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming DeadlineNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/19/20245:45AMPR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/14/20249:00AMBusiness WireAmylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of DirectorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/14/20245:50AMPR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/11/20248:44AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/11/20245:50AMPR Newswire (US)Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

Your Recent History

USOTC
ITUP
Interups (CE)
USOTC
AABB
Asia Broadband (PK)
USOTC
SFLM
SFLMaven (PK)
USOTC
ENZC
Enzolytics (PK)
NYSE
AMC
AMC Entertainment
USOTC
RONN
Ronn Motor (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
ECSL
Ecare Solutions (PK)
NASDAQ
NB
NioCorp Developments
USOTC
CGAC
Code Green Apparel (PK)
USOTC
SPZI
Spooz (PK)
USOTC
IDVV
International Endeavors (PK)
NASDAQ
AMRN
Amarin
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
TSLA
Tesla
USOTC
SMCE
SMC Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved